Mifepristone
- Generic Name
- Mifepristone
- Brand Names
- Korlym, Mifegymiso
- Drug Type
- Small Molecule
- Chemical Formula
- C29H35NO2
- CAS Number
- 84371-65-3
- Unique Ingredient Identifier
- 320T6RNW1F
- Background
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary c...
- Indication
For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
- Associated Conditions
- Hyperglycemia
- Associated Therapies
- Medically induced abortion
Trial of Mifepristone for Fibroids
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 70
- Registration Number
- NCT00133705
- Locations
- 🇺🇸
University of Rochester School of Medicine & Dentistry, Rochester, New York, United States
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
- Conditions
- Interventions
- First Posted Date
- 2005-08-16
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 257
- Registration Number
- NCT00130676
- Locations
- 🇺🇸
NMDNJ, Newark, New Jersey, United States
🇺🇸CNRI-LA, Pico Rivera, California, United States
🇺🇸Neurobehavioral Research Company, Lawrence, New York, United States
An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
- Conditions
- Interventions
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 104
- Registration Number
- NCT00128505
- Locations
- 🇧🇬
Svetlozar H Haralanov Ph.D., Sofia, Bulgaria
🇭🇷Vera Folnegovic-Smalc M.D/Ph.D, Zagreb, Croatia
🇧🇬Vihra Milanova M.D., Sofia, Bulgaria
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
- Conditions
- Interventions
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 443
- Registration Number
- NCT00128479
- Locations
- 🇺🇸
Saint Vincent Catholic Medical Centers of New York, Staten Island, New York, United States
🇺🇸CNS Research Institute (CRI), Philadelphia, Pennsylvania, United States
🇺🇸Harmony Research, Johnson City, Tennessee, United States
Mifepristone as Adjunctive Therapy in Alzheimer's Disease
- Conditions
- First Posted Date
- 2005-03-07
- Last Posted Date
- 2009-12-11
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 160
- Registration Number
- NCT00105105
- Locations
- 🇺🇸
Clinical Trials Research Services, Pittsburgh, Pennsylvania, United States
🇺🇸Clinical Physiology Associates, Ft. Myers, Florida, United States
🇺🇸International Clinical Research Associates, Virginia Beach, Virginia, United States
Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People
- Conditions
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 48
- Registration Number
- NCT00099645
- Locations
- 🇺🇸
University of Minnesota, ACTU, Minneapolis, Minnesota, United States
🇺🇸Georgetown University CRS (GU CRS), Washington, District of Columbia, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
Clinical Trial of Mifepristone for Bipolar Depression
- Conditions
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 110
- Registration Number
- NCT00043654
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.